特朗普政府官员正在推动放宽睾酮药物的处方限制。[1]卫生部长罗伯特·F·肯尼迪 Jr. 支持这一举措。[1]与此同时，国防部长皮特·赫格塞特宣布美国国防部将开始为士兵筛查低睾酮并提供激素治疗。[1]
监管层面，美国食品药品监督管理局已采取措施为该类药物铺路。FDA 去年移除了这类药物关于心脏风险的重要安全警告。[1]上月，FDA 提议重写处方说明书以涵盖与年龄相关的症状。[1]
医学研究为这些行动提供了部分依据。2023年 FDA 强制进行的一项研究显示，5000名有心脏病史的男性服用睾酮凝胶两年后，心脏病发作和中风风险没有差异。[1]
然而，医学专家对此持谨慎态度。专家警告睾酮治疗可能抑制精子生成，对生育能力构成影响。[1]这些警告突显了在放宽处方限制时需要平衡潜在益处与风险。
The Trump administration is moving to relax prescribing requirements for testosterone drugs, with Health Secretary Robert F. Kennedy Jr. backing the effort [1]. The Department of Defense has announced plans to screen soldiers for low testosterone and provide hormone treatment [1].
The Food and Drug Administration removed a bold safety warning about heart risks from testosterone medications last year [1] and proposed in recent weeks to revise labeling to include age-related symptoms [1]. A 2023 FDA-mandated study following 5,000 men with a history of heart disease who used testosterone gel for two years found no difference in rates of heart attacks and strokes compared to controls [1].
Despite these regulatory shifts and evidence supporting testosterone's benefits for sexual health in specific populations, medical experts caution against overtreatment. Testosterone therapy can suppress sperm production and damage fertility, according to specialists [1].